A prediction study on radiation-induced second malignancies for IMRT treatment delivery

Technology in Cancer Research and Treatment

Volumn 8, Issue 2, 2009, Pages 141-148

  Stathakis, Sotirios ^a   Roland, Teboh ^a   Papanikolaou, Niko ^a   Li, Jinseng ^b   Ma, Charlie ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Conventional radiotherapy; IMRT; Monte Carlo; Second malignancy

Indexed keywords

ARTICLE; BREAST TUMOR; CANCER RISK; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; HEAD AND NECK TUMOR; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; LUNG TUMOR; MONTE CARLO METHOD; PROSTATE TUMOR; RADIATION DOSE; RISK ASSESSMENT; SECOND CANCER;

EID: 65949119342     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460900800207     Document Type: Article

References (31)

1. Bey, P., C. Carrie, V. Beckendorf, C. Ginestet, P. Aletti, G. Madelis, E. Luporsi, P. Pommier, D. Cowen, L. Gonzague-Casabianca, M. Simonian-Sauve, P. Maingon, S. Naudy, J. Lagrange, and S. Marcie. Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results. Int J Radiat Oncol Biol Phys 48, 513-517 (2000).
2. Hanks, G. E., A. L. Hanlon, B. Epstein, and E. M. Horwitz. Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phys 54, 427-435 (2002).
3. Hanks, G. E., A. L. Hanlon, T. E. Schultheiss, W. H. Pinover, B. Movsas, B. E. Epstein, and M. A. Hunt, Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41, 501-510 (1998).
4. Lyons, J. A., P. A. Kupelian, D. S. Mohan, C. A. Reddy, and E. A. Klein. Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 55, 85-90 (2000).
5. Pollack, A., L. G. Smith, and A. C. von Eschenbach. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48, 507-512 (2000).
6. Pollack, A., G. K. Zagars, G. Starkschall, J. A. Antolak, J. J. Lee, E. Huang, A. C. von Eschenbach, D. A. Kuban, and I. Rosen. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53, 1097-1105 (2002).
7. Zelefsky, M. J., S. A. Leibel, P. B. Gaudin, G. J. Kutcher, N. E. Fleshner, E. S. Venkatramen, V. E. Reuter, W. R. Fair, C. C. Ling, and Z. Fuks. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41, 491-500 (1998).
8. Stathakis, S., J. Li, and C. C. Ma. Monte Carlo determination of radiation-induced cancer risks for prostate patients undergoing intensity-modulated radiation therapy. J Appl Clin Med Phys 8, 2685 (2007).
9. Brenner, D. J., R. E. Curtis, E. J. Hall, and E. Ron. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88, 398-406 (2000).
10. Boice, J. D., Jr., N. E. Day, A. Andersen, L. A. Brinton, R. Brown, N. W. Choi, E. A. Clarke, M. P. Coleman, R. E. Curtis, J. T. Flannery, and et al., Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 74, 955-975 (1985).
11. Movsas, B., A. L. Hanlon, W. Pinover, and G. E. Hanks, Is there an increased risk of second primaries following prostate irradiation? Int J Radiat Oncol Biol Phys 41, 251-255 (1998). (Pubitemid 28243533)
12. Rogers, D. W., B. A. Faddegon, G. X. Ding, C. M. Ma, J. We, and T. R. Mackie. BEAM: a Monte Carlo code to simulate radiotherapy treatment units. Med Phys 22, 503-524 (1995).
13. Kry, S. F., U. Titt, D. Followill, F. Ponisch, O. N. Vassiliev, R. A. White, M. Stovall, and M. Salehpour. A Monte Carlo model for out-of-field dose calculation from high-energy photon therapy. Med Phys 34, 3489-3499 (2007).
14. Ma, C. M., J. S. Li, T. Pawlicki, S. B. Jiang, J. Deng, R. A. Price, L. Chen, L. Wang, E. Fourkal, L. H. Qin, J. Yang, and W. Xiong. MCSIM - A Monte Carlo dose calculation tool for radiation therapy. Proc. of the XVIth International Conference on the Use of Computers in Radiation Therapy, 515-519 (2004).
15. Price, R. A., O. Chibani, and C. M. Ma. Shielding evaluation for IMRT implementation in an existing accelerator vault. J Appl Clin Med Phys 4, 231-238 (2003).
16. Hall, E. J. and C. S. Wuu. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56, 83-88 (2003).
17. Upton, A. C. The dose-response relation in radiation-induced cancer. Cancer Res 21, 717-729 (1961).
18. Blettner, M. and J. D. Boice, Jr., Radiation dose and leukaemia risk: general relative risk techniques for dose-response models in a matched case-control study. Stat Med 10, 1511-1526 (1991).
19. Boice, J. D., Jr., M. Blettner, R. A. Kleinerman, M. Stovall, W. C. Moloney, G. Engholm, D. F. Austin, A. Bosch, D. L. Cookfair, E. T. Krementz, and et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 79, 1295-1311 (1987).
20. Curtis, R. E., J. D. Boice, Jr., M. Stovall, L. Bernstein, E. Holowaty, S. Karjalainen, F. Langmark, P. C. Nasca, A. G. Schwartz, M. J. Schymura, and et al. Relationship of leukemia risk to radiation dose following cancer of the uterine corpus. J Natl Cancer Inst 86, 1315-1324 (1994).
21. Sachs, R. K. and D. J. Brenner. Solid tumor risks after high doses of ionizing radiation. Proc Natl Acad Sci USA 102, 13040-13045 (2005).
22. Gilbert, E. S., M. Stovall, M. Gospodarowicz, F. E. Van Leeuwen, M. Andersson, B. Glimelius, T. Joensuu, C. F. Lynch, R. E. Curtis, E. Holowaty, H. Storm, E. Pukkala, M. B. van't Veer, J. F. Fraumeni, J. D. Boice, Jr., E. A. Clarke, and L. B. Travis. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat Res 159, 161-173 (2003).
23. Travis, L. B., D. A. Hill, G. M. Dores, M. Gospodarowicz, F. E. van Leeuwen, E. Holowaty, B. Glimelius, M. Andersson, T. Wiklund, C. F. Lynch, M. B. Van't Veer, I. Glimelius, H. Storm, E. Pukkala, M. Stovall, R. Curtis, J. D. Boice, Jr., and E. Gilbert. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Jama 290, 465-475 (2003).
24. van Leeuwen, F. E., W. J. Klokman, M. Stovall, E. C. Dahler, M. B. van't Veer, E. M. Noordijk, M. A. Crommelin, B. M. Aleman, A. Broeks, M. Gospodarowicz, L. B. Travis, and N. S. Russell. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95, 971-980 (2003).
25. Kry, S. F., M. Salehpour, U. Titt, R. A. White, M. Stovall, and D. Followill. Monte Carlo study shows no significant difference in second cancer risk between 6- and 18-MV intensity-modulated radiation therapy. Radiother Oncol (2009).
26. Walton, A. and A. L. Broadbent, Radiation-induced second malignancies. J Palliat Med 11, 1345-1352 (2008).
27. Etzel, R. Risk of ionizing radiation exposure to children 1998 A subject review. American Acadademy of Pediatrics. Committee on Environmental Health. Pediatrics 101, 717-719 (1998).
28. Rubino, C., A. Shamsaldin, M. G. Le, M. Labbe, J. M. Guinebretiere, J. Chavaudra, and F. de Vathaire. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat 89, 277-288 (2005). (Pubitemid 43293076)
29. Stone, H. B., C. N. Coleman, M. S. Anscher, and W. H. McBride. Effects of radiation on normal tissue: consequences and mechanisms. Lancet Oncol 4, 529-536 (2003).
30. Fowler, J. F. The first James Kirk memorial lecture. What next in fractionated radiotherapy? Br J Cancer Suppl 6, 285-300 (1984).
31. Thames, H. D., Jr., H. R. Withers, L. J. Peters, and G. H. Fletcher. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8, 219-226 (1982).